COAG Hemab Therapeutics Holdings, Inc.
Fundamentals / CIK 0002114044 / USDHemab Therapeutics Holdings, Inc. reported $442.7M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open COAG in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$430.2M Total debt: $965K
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Research & Development | $24.64M | $20.34M | $19.46M | $14.55M | $12.87M | $14.10M |
| Selling, General & Admin | $5.12M | $5.74M | $4.15M | $2.50M | $3.18M | $2.46M |
| Total Operating Expenses | $29.76M | $26.08M | $23.61M | $17.05M | $16.06M | $16.56M |
| Operating Income | -$29.76M | -$26.08M | -$23.61M | -$17.05M | -$16.06M | -$16.56M |
| EBITDA | -$29.68M | -$26.00M | -$23.54M | -$16.98M | -$15.98M | -$16.48M |
| Interest Income | $3.38M | $2.86M | $1.22M | $215K | $335K | $473K |
| Income Before Tax | -$26.61M | -$24.05M | -$22.68M | -$16.97M | -$12.21M | -$15.50M |
| Income Tax Expense | $693K | $97K | $12K | $98K | $4.0K | -$190K |
| Net Income | -$27.30M | -$24.15M | -$22.69M | -$17.07M | -$12.21M | -$15.31M |
| Basic EPS | -$0.58 | -$0.80 | -$1.09 | -$18.04 | -$12.91 | -$0.74 |
| Diluted EPS | -$0.58 | -$0.80 | -$1.09 | -$18.04 | -$12.91 | -$0.74 |
| Basic Shares Outstanding | 46.7M | 30.1M | 20.8M | 946.0K | 946.0K | 20.8M |
| Diluted Shares Outstanding | 46.7M | 30.1M | 20.8M | 946.0K | 946.0K | 20.8M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $239.1M | $237.4M | $49.86M | $87.97M |
| Short-Term Investments | $191.1M | $220.1M | $113.7M | $97.51M |
| Cash & Short-Term Investments | $430.2M | $457.5M | $163.5M | $185.5M |
| Total Current Assets | $438.2M | $464.0M | $169.4M | $192.6M |
| Property, Plant & Equipment, Net | $555K | $596K | $648K | $609K |
| Other Non-Current Assets | $3.15M | $2.29M | $4.24M | $531K |
| Total Non-Current Assets | $4.55M | $3.78M | $5.83M | $2.23M |
| Total Assets | $442.7M | $467.8M | $175.3M | $194.8M |
| Accounts Payable | $5.95M | $6.23M | $5.68M | $5.73M |
| Other Current Liabilities | $1.20M | $990K | $2.66M | $340K |
| Total Current Liabilities | $12.94M | $12.94M | $13.19M | $10.68M |
| Total Non-Current Liabilities | $503K | $566K | $519K | $573K |
| Total Liabilities | $13.44M | $13.51M | $13.71M | $11.25M |
| Total Debt (incl. Leases) | $965K | $1.03M | $1.06M | $1.22M |
| Retained Earnings | -$256.0M | -$228.7M | -$204.5M | -$181.9M |
| Accumulated Other Comp. Income | -$2.65M | -$2.75M | -$439K | $175K |
| Total Stockholders' Equity | $429.3M | $454.3M | -$198.6M | -$176.6M |
| Total Equity | $429.3M | $454.3M | -$198.6M | -$176.6M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$27.30M | -$24.15M | -$22.69M | -$17.07M | -$12.21M | -$15.31M |
| Depreciation & Amortization | $75K | $75K | $73K | $76K | $77K | $75K |
| Change in Payables | -$280K | $550K | -$52K | $872K | -$2.32M | $2.88M |
| Operating Cash Flow | -$28.29M | -$22.64M | -$21.58M | -$16.39M | -$15.33M | -$13.03M |
| Capital Expenditure | -$34K | -$23K | -$112K | $0 | $0 | -$16K |
| Free Cash Flow | -$28.32M | -$22.66M | -$21.70M | -$16.39M | -$15.33M | -$13.05M |
| Purchases of Investments | $0 | -$132.5M | -$15.73M | $0 | $0 | -$19.95M |
| Investing Cash Flow | $30.10M | -$107.4M | -$15.85M | $0 | $21.50M | -$5.99M |
| Financing Cash Flow | $47K | $317.6M | -$460K | -$30K | -$30K | -$29K |
| Net Change in Cash | $1.78M | $187.5M | -$38.11M | -$16.43M | $6.14M | -$19.06M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 33.86x | 35.85x | 12.85x | -- | -- | -- |
| Quick Ratio | 33.25x | 35.34x | 12.40x | -- | -- | -- |
| Debt to Equity | 0.00x | 0.00x | -- | -- | -- | -- |